H Venture Partners launches venture studio focused on microbiome tech (June 25, 2024) | By Dominic-Madori Davis. H Venture Partners is launching a venture studio that will focus on sourcing microbiome technologies and materials that can be commercialized and turned into startups. The firm said on Friday that it will source talent who can solve health
Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer (May 2, 2024) | By Laura Asbjornsen, Portfolio News. Exciting news today for Forbion portfolio company Mariana Oncology. The company announces a landmark acquisition deal with Novartis worth $1 billion in cash upfront and up to $750 million in potential milestone payments. This
Asgard Gets $32M Series A Backing from J&J, Novo and Boehringer (March 15, 2024) | By Tyler Patchen, BioSpace. Swedish-based gene therapy biotech Asgard Therapeutics has closed a €30 million ($32.6 million) Series A to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology, the company announced Thursday. The funding round was led by
Novartis Pays $90M for Molecules That Could Take STING Out of Inflammation Placing research in the hands of a large pharmaceutical company is a goal of many biotech companies. IFM Therapeutics has now done it three times and its latest deal is the second time Novartis is the acquirer. (March 13, 2024) | By Frank
Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections (January 5, 2024) | By Kellie Hotz, Clarametyx Biosciences. COLUMBUS, Ohio – January 5, 2024 – Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the successful completion of a
LEGOCHEM BIOSCIENCES ANNOUNCES LICENSE AGREEMENT FOR LCB84 TROP2-TARGETED ADC LegoChem Biosciences to receive up to potentially USD1.7 billion in total, including an upfront payment and option exercise fee (December 26, 2023) | By DAEJEON, South Korea–(BUSINESS WIRE). LegoChem Biosciences to receive up to potentially USD1.7 billion in total, including an upfront payment and option exercise
Sanofi signs $140m small molecule discovery deal with Aqemia The multi-year research collaboration will involve Aqemia’s AI platform, with the company receiving up to $140m from Sanofi. (December 5, 2023) | By Jenna Philpott. Sanofi has entered a multi-year research collaboration deal with French pharmatech Aqemia to develop small molecule drug candidates for several different
Merck to Acquire Caraway Therapeutics, Inc. Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases (November 21, 2023) | By Merck & Co., Inc. RAHWAY, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have
BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases (November 28, 2023) | By Kate Goodwin Bristol Myers Squibb is upping the ante in its partnership with Avidity Biosciences. The San Diego-based biopharma announced Tuesday an expansion of its previous collaboration with BMS,
Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs (September 27, 2023) | By Andrew Dunn, Biopharma Correspondent In its latest Big Pharma deal, Ginkgo Bioworks will work with Pfizer to develop new RNA drugs, the Boston-based synthetic biology startup exclusively told Endpoints News. The two aren’t disclosing many specifics
